L
Laurence E. Burgess
Researcher at University of Texas at Austin
Publications - 57
Citations - 1127
Laurence E. Burgess is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Lactol & Carboxylic acid. The author has an hindex of 16, co-authored 57 publications receiving 904 citations. Previous affiliations of Laurence E. Burgess include Icos & Celgene.
Papers
More filters
Journal ArticleDOI
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.
Fell Jay Bradford,John P. Fischer,Brian R. Baer,James F. Blake,Karyn Bouhana,David Briere,Karin D. Brown,Laurence E. Burgess,Aaron C. Burns,Michael Burkard,Harrah Chiang,Mark Joseph Chicarelli,Cook Adam,John Gaudino,Jill Hallin,Lauren Hanson,Dylan P. Hartley,Hicken Erik James,Gary P. Hingorani,Ronald Jay Hinklin,Macedonio J. Mejia,Peter Olson,Jennifer N. Otten,Susan P. Rhodes,Martha Rodriguez,Pavel Y. Savechenkov,Darin Smith,Niranjan Sudhakar,Francis X. Sullivan,Tony Pisal Tang,Guy Vigers,Lance Wollenberg,James G. Christensen,Matthew A. Marx +33 more
TL;DR: The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.
Patent
Compounds useful for inhibiting Chk1
Kathleen S. Keegan,Edward A. Kesicki,John Gaudino,Cook Adam,Cowen Scott Douglas,Laurence E. Burgess +5 more
TL;DR: Aryl and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed in this paper.
Journal ArticleDOI
Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
C. Todd Eary,Zachary Jones,Robert D. Groneberg,Laurence E. Burgess,David A. Mareska,Mark D. Drew,James F. Blake,Ellen R. Laird,Devan Balachari,Michael O'sullivan,Andrew Allen,Vivienne Marsh +11 more
TL;DR: This communication will describe the SAR and synthesis of a series of substituted tetrahydroquinoxaline CETP inhibitors from early mu lead to advanced enantiomerically pure analogs.
Patent
Materials and methods to potentiate cancer treatment
James Halbrook,Edward A. Kesicki,Laurence E. Burgess,Schlachter Stephen T,Charles Todd Eary,Justin G. Schiro,Hongmei Huang,Michael Evans,Yongxin Han +8 more
TL;DR: In this article, compounds of Formula (I) that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, and methods to sensitize cells the agents that cause DNA lesions are disclosed.
Journal ArticleDOI
Potent selective nonpeptidic inhibitors of human lung tryptase.
Laurence E. Burgess,Brad Newhouse,Prabha N. Ibrahim,James P. Rizzi,Mohammed A. Kashem,Ann Hartman,Barbara J. Brandhuber,Clifford D. Wright,David S. Thomson,Guy Vigers,Kevin Koch +10 more
TL;DR: A hypothesis that tethered symmetrical inhibitors might bridge two adjacent active sites was explored via a rationally designed series of bisbenzamidines, which demonstrated a remarkable distanced-defined structure-activity relationship against human tryptase with one series possessing subnanomolar potencies.